Endostatin in combination with docetaxel for patients with NSCLC who resistant to the prior EGFR-TKI agent treatment.

Trial Profile

Endostatin in combination with docetaxel for patients with NSCLC who resistant to the prior EGFR-TKI agent treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2012

At a glance

  • Drugs Endostatin (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EnDOC
  • Most Recent Events

    • 21 May 2012 Actual end date (Dec 2010) added as reported by Chinese Clinical Trial Register record.
    • 24 Jan 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register record (ChiCTR-ONC09000355).
    • 29 Dec 2011 Additional trial acronym (EnDOC) identified as reported by Chinese Clinical Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top